The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

"It is estimated that by 2030, 30 million GLP-1 [receptor agonist] prescriptions ... The cause is unknown but might be similar to the mechanism of worsened diabetic retinopathy," Warner noted.

These are likely mechanisms by which GLP-1 may impact neuropsychiatric conditions.” — Ziyad Al-Aly, MD “I think there is clearly (an) added benefit for several conditions. For example ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i. Real-world data show ... patients with moderate to advanced CKD, although ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...